20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement

20/20 Biolabs, Inc.

Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.
Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.
Completed $5.0M private placement Feb 2026; up to $40M available in tranches.
MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.
Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

20/20 Biolabs, Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income ($3.7) million.

Period: the full year ended December 31, 2025
Revenue: $2.0 million
Net income: ($3.7) million
Result: reported results

Exact text from the filing

Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024. ● Deferred revenue totaled approximately $0.4 million as of December 31, 2025. ● Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024. ● Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024. ● FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

20/20 Biolabs, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-037770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.